N/A
N=45
MyVoice:Rheum Decision Aid for Women With Rheumatic Diseases
Rheumatic Diseases · Physician-Patient Relations · Contraception
Bottom Line
View on ClinicalTrials.gov: NCT04879745 ↗Enrolled (actual)
45
Serious AEs
0.0%
Results posted
Apr 2024
Primary outcome: Primary: Acceptability of Intervention — 4.45; 3.97 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- MyVoice:Rheum (Other); Pamphlet (Other)
- Age
- Adult · 18+ yrs
- Sex
- Female
- Sponsor
- University of Pittsburgh
- Primary completion
- Dec 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Acceptability of Intervention |
4.45; 3.97 | — |
| PRIMARY Intervention Appropriateness Measure |
4.48; 4.11 | — |
| PRIMARY System Usability Scale |
83.06; 79.32 | — |
Summary
This is a pilot trial to assess feasibility and acceptability of MyVoice:Rheum vs. a patient pamphlet among female patients ages 18-44 (n=40) who receive rheumatology care.
• Hypothesis: MyVoice:Rheum will be feasible and acceptable to patients who receive rheumatology care.
Eligibility Criteria
Inclusion Criteria
Patients must have at least one of four rheumatic diseases diagnosed by a rheumatologist: rheumatoid arthritis (RA), systemic sclerosis (SSc), myositis, Sjogren's syndrome, vasculitis, spondyloarthritis, and systemic lupus erythematosus (SLE).
Patients must read and speak in English as a Spanish-language version of the tool has not yet been developed
Access to a smart phone, personal computer, or tablet.
Exclusion Criteria
- Women who have had prior hysterectomy or sterilization, or are pregnant.
Data sourced from ClinicalTrials.gov (NCT04879745). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.